Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Orphan Drugs Market Snapshot
Chapter 4. Global Orphan Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Clinical Trial/Pipeline Analysis Snapshot
4.8. COVID 19 Impact on Pharmaceutical Industry
Chapter 5. Market Segmentation 1: Drug Types Estimates & Trend Analysis
5.1. Drug Types & Market Share, 2020 & 2028
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2020 to 2028 for the following Drug Types:
5.2.1. Biological
5.2.2. Non-Biological
Chapter 6. Market Segmentation 2: Top Selling Drugs & Trend Analysis
6.1. Top Selling Drugs & Market Share, 2020 & 2028
6.2. Market Size (Value)& Forecasts and Trend Analyses, 2020 to 2028 for the following Top Selling Drugs:
6.2.1. Revlimid
6.2.2. Rituxan
6.2.3. Copaxone
6.2.4. Opdivo
6.2.5. Keytruda
6.2.6. Imbruvica
6.2.7. Avonex
6.2.8. Sensipar
6.2.9. Soliris
6.2.10. Other Top Selling Drugs
Chapter 7. Market Segmentation 3: Therapy Area & Trend Analysis
7.1. Therapy Area & Market Share, 2020 & 2028
7.2. Market Size (Value)& Forecasts and Trend Analyses, 2020 to 2028 for the following Therapy Area
7.2.1. Oncology
7.2.2. Blood
7.2.3. Central Nervous System
7.2.4. Endocrine
7.2.5. Cardiovascular
7.2.6. Respiratory
7.2.7. Immunomodulatory
7.2.8. Other Disease Types
Chapter 8. Orphan Drugs Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2020-2028
8.1.2. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2020-2028
8.1.3. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2020-2028
8.1.4. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by country, 2020-2028
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe Orphan Drugs Market revenue (US$ Million) Drug Types, 2020-2028
8.2.2. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2020-2028
8.2.3. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2020-2028
8.2.4. Europe Orphan Drugs Market revenue (US$ Million) by country, 2020-2028
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Orphan Drugs Market revenue (US$ Million) Drug Types, 2020-2028
8.3.2. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2020-2028
8.3.3. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2020-2028
8.3.4. Asia Pacific Orphan Drugs Market revenue (US$ Million) by country, 2020-2028
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America Orphan Drugs Market revenue (US$ Million) Drug Types, 2020-2028
8.4.2. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2020-2028
8.4.3. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2020-2028
8.4.4. Latin America Orphan Drugs Market revenue (US$ Million) by country, 2020-2028
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2020-2028
8.5.2. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2020-2028
8.5.3. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2020-2028
8.5.4. MEA revenue Orphan Drugs Market revenue (US$ Million) by country, (US$ Million) 2020-2028
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Bristol-Myers Squibb Company
9.2.2. Celgene Corporation
9.2.3. F. Hoffmann-La Roche Ltd
9.2.4. Amgen
9.2.5. Biogen
9.2.6. Bayer
9.2.7. Novartis AG
9.2.8. GlaxoSmithKline plc
9.2.9. Johnson & Johnson
9.2.10. AbbVie Inc
9.2.11. Eli Lilly and Company
9.2.12. Alexion Pharmaceuticals
9.2.13. Shire
9.2.14. Novo Nordisk
9.2.15. AstraZeneca
9.2.16. Eisai
9.2.17. Daiichi Sankyo
9.2.18. Merck
9.2.19. Teva Pharmaceutical Industries
9.2.20. Actelion Pharmaceuticals Ltd.
9.2.21. Aegerion Pharmaceuticals
Other Prominent Players